64
Participants
Start Date
April 21, 2023
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2029
Imlifidase administered in the ConfIdeS study
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
Best available treatment administered in the ConfIdeS study
Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
RECRUITING
New York University (NYU) Langone Transplant Institute, NYU Langone Health, New York
RECRUITING
Columbia University, New York
RECRUITING
John Hopkins Hospital, Baltimore
RECRUITING
University of Alabama at Birmingham (UAB) Hospital, Birmingham
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Northwestern University, Dept. General Surgery, Div. Transplantation, Chicago
RECRUITING
University of Chicago, Department of Surgery, Clinical Research Center, Chicago
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Houston Methodist Hospital, Houston
RECRUITING
Methodist Hospital Specialty and Transplant, San Antonio
RECRUITING
Cedars-Sinai Medical Center, Los Angeles
RECRUITING
University of Washington Medical Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Cooperman Barnabas Medical Center, Livingston
Lead Sponsor
Hansa Biopharma AB
INDUSTRY